A Phase 1b/2 Multicenter, Randomized, Umbrella Study Evaluating Novel Treatment Combinations in Melanoma (MORPHEUS-MELANOMA)

Georgina V. Long,1 Rodolfo N. Amara,1 Ahmad A. Tarhini,1 Paola A. Asciento,1 Edward Cha,1 Oliverio Cirovic,1 Denise Cotting,1 Volker Teichgraber,1 Christian U. Blank.1

1Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia; University of Texas MD Anderson Cancer Center, Houston TX, USA; I. Leo-Moffitt Cancer Center and Research Institute, Tampa, FL, USA; Turku University Hospital (VTTK, PFUS, PCU), Turku, Finland; Genentech, Inc. South San Francisco, CA, USA; NSH, Netherfield La Roche AG, Basel, Switzerland; The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

BACKGROUND

- Immune checkpoint inhibitors (ICIs) targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) have improved overall survival (OS) in patients with advanced melanoma.
- Neoadjuvant ICIs have also been shown to induce tumor regression in patients with metastatic melanoma and improve clinical benefit.

OBJECTIVES

- To determine the efficacy, safety, and pharmacology of various treatment combinations in patients with cancer immunotherapy (CT) naïve, resectable stage III melanoma and in patients with previously treated stage IV melanoma.

METODS

Study Design

MORPHEUS-MELANOMA is a phase II/III multicenter, randomized, open-label, umbrella study in patients with treatment-naïve, resectable stage III (Cohort 1) or previously treated stage IV (Cohort 2) melanoma (Figure 1). (CT, cancer immunotherapy; CEA, carcinoembryonic antigen; PD-L1, programmed death ligand 1; RECIST v1.1, Response Evaluation Criteria in Solid Tumors, version 1.1.)

Figure 1. Study design.

Treatments and Procedures

- In Cohort 1, patients will be randomly assigned to receive 6 weeks of intravenous neoadjuvant treatment in one of 3 experimental arms or a comparator arm (Figure 1).
- In Cohort 2, patients will be randomly assigned to receive intravenous atezolizumab + tiragolumab followed by a surgical procedure (Figure 1).

Endpoints

- Key endpoints for Cohort 1 and 2 are listed in Table 2.

Table 2. Study Endpoints

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Cohort 1</th>
<th>Cohort 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

DISCUSSIONS

GAL reports honoraria for a consulting/advisory role from Agence Inca, Arroyo Inc, Arroyo Biopharma Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Evasion Biotech A/S, Hovon AG (S Beacon Company), Highlight Therapeutics SL, Merck Sharp & Dohme Inc; RNA reports consulting/advisory role for Bristol Myers Squibb, Genentech/Roche, InflaRx GmbH, Novartis, and institutional research funding from Amgen Inc, Array Biopharma Inc, Boehringer Ingelheim, Bristol-Myers Squibb, Cancer Research UK, Celgene Corporation, Genentech/Roche, Immunocore Ltd, Janssen Biotech Inc, Merck, Novartis, Pfizer, and Roche; AT reports consulting/advisory roles for BioNTech, Bristol-Myers Squibb, Easai, Genentech/Roche, Immucor, Immunocore, Medarex, Merck Sharp & Dohme, Novartis, Roche, and Sanofi-Genzyme; CUB reports consulting/advisory roles for Amgen Inc, Bristol-Myers Squibb, and EMD Serono; EV reports consulting/advisory roles for Agenus Inc, Amgen Inc, Array Biopharma Inc, Boehringer Ingelheim, Celldex, Celularity, Celltrion, Genentech/Roche, Iovance, and Innate Immunotherapies; GVL reports honoraria for a consulting/advisory role from Agenus Inc, Amgen Inc, Array Biopharma Inc, Boehringer Ingelheim, Celldex, Celularity, Celltrion, Genentech/Roche, Iovance, and Innate Immunotherapies; and a pending patent (WO 2021/177822 A1) with Immagene BV.

ACKNOWLEDGMENTS

This study is being funded by F Hoffmann-La Roche Ltd. Editorial assistance was provided by Melanie Swinburne, MSc, of ApolloCom (San Francisco, CA) and funded by F Hoffmann-La Roche Ltd.

Contact georgina.long@sydney.edu.au for questions or comments.

REFERENCES

10. For more information, please contact Roche/Genentech trials at global.rochegenentechtrials@roche.com or visit https://forpatients.roche.com/trialsgeneticstrialsmelanoma/evaluating-the-efficacy-and-safety-ofmultiple--23342.html

DISCLOSURES

GA, GAL, and RNA report institutional research funding from Bristol-Myers Squibb, Genentech/Roche, EMD Serono, and institutional research funding from Bristol-Myers Squibb, Roche, and Sanofi-Genzyme; EV reports consulting/advisory roles for BioNTech, Bristol-Myers Squibb, Easai, Genentech/Roche, Immunocore, Medarex, Merck Sharp & Dohme, Novartis, Roche, and Sanofi-Genzyme; AT reports consulting/advisory roles for BioNTech, Bristol-Myers Squibb, Easai, Genentech/Roche, Immunocore, Medarex, Merck Sharp & Dohme, Novartis, Roche, and Sanofi-Genzyme; CUB reports consulting/advisory roles for Amgen Inc, Bristol-Myers Squibb, and EMD Serono; EV reports consulting/advisory roles for Agenus Inc, Amgen Inc, Array Biopharma Inc, Boehringer Ingelheim, Celldex, Celularity, Celltrion, Genentech/Roche, Iovance, and Innate Immunotherapies; GVL reports honoraria for a consulting/advisory role from Agenus Inc, Amgen Inc, Array Biopharma Inc, Boehringer Ingelheim, Celldex, Celularity, Celltrion, Genentech/Roche, Iovance, and Innate Immunotherapies; and a pending patent (WO 2021/177822 A1) with Immagene BV.


For more information, please contact Roche/Genentech trials at global.rochegenentechtrials@roche.com or visit https://forpatients.roche.com/trialsgeneticstrialsmelanoma/evaluating-the-efficacy-and-safety-ofmultiple--23342.html

Figure 2. Participating countries.